Takeda Pharmaceutical (TKPHF) Profit After Tax (2017 - 2026)

Takeda Pharmaceutical's Profit After Tax history runs 10 years deep, the most recent figure standing at -$154.7 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 108.52% year-over-year to -$154.7 million; the TTM figure through Mar 2026 stood at $7.0 billion (down 11.3% YoY), while the FY2026 annual figure was $1.3 billion, up 79.69% from the prior year.
• Profit After Tax was -$154.7 million for Q1 2026 at Takeda Pharmaceutical, down from $913.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $4.7 billion in Q3 2025 to a low of -$154.7 million in Q1 2026.
• Historically, Profit After Tax has averaged $1.3 billion across 5 years, with a median of $843.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax soared 9083.69% in 2025, then slumped 108.52% in 2026.
• A 5-year view of Profit After Tax shows it stood at $843.4 million in 2022, then gained by 27.7% to $1.1 billion in 2023, then slumped by 30.86% to $744.6 million in 2024, then climbed by 22.7% to $913.6 million in 2025, then tumbled by 116.93% to -$154.7 million in 2026.
• The last three Profit After Tax figures came in at -$154.7 million (Q1 2026), $913.6 million (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.